Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

60.41 -1.78 (-2.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Swing Trading Stock Watchlist For The Week Of Sept. 6 ↗
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look. 
Via Talk Markets
News headline image
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday ↗
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Cytokinetics ↗
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter: 
Via Benzinga
News headline image
Analyst Ratings for Cytokinetics ↗
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Where Cytokinetics Stands With Analysts ↗
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: 
Via Benzinga
News headline image
Cytokinetics Posts Cohort 3 Data From Aficamten Trial In Heart Disease Patients ↗
Cytokinetics Incorporated (NASDAQ: CYTK) has announced  
Via Benzinga
News headline image
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M ↗
 
Via Benzinga
News headline image
Recap: Cytokinetics Q2 Earnings ↗
Cytokinetics (NASDAQ:CYTK) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics beat estimated... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
News headline image
What 5 Analyst Ratings Have To Say About Cytokinetics ↗
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
News headline image
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22 ↗
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing... 
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. 
Via Benzinga
News headline image
Cytokinetics: Q1 Earnings Insights ↗
Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated... 
Via Benzinga
News headline image
70 Biggest Movers From Friday ↗
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... 
Via Benzinga
News headline image
48 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:... 
Via Benzinga
News headline image
Cytokinetics's Omecamtiv Mecarbil Shows No Effect On Exercise Capacity In Heart Failure Patients ↗
 
Via Benzinga
News headline image
Cytokinetics: Q4 Earnings Insights ↗
Cytokinetics (NASDAQ:CYTK) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
News headline image
33 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 35.9% to $4.6899 after the company announced an integration with Amazon Ads' demand-side platform. Absci... 
Via Benzinga
News headline image
56 Biggest Movers From Friday ↗
Gainers Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share. China HGS Real Estate Inc. (NASDAQ: HGSH) shares... 
Via Benzinga
News headline image
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact ↗
Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 ↗
Upgrades According to Loop Capital, the prior rating for Williams-Sonoma Inc (NYSE: 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Cytokinetics ↗
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK)... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 ↗
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE: 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.